This section contains information about Galapagos NV’s business for stockholders, potential investors, financial analysts and media.
Do you want to receive our press releases?
Mechelen, Belgium, September 22nd, 2004 – Galapagos Genomics NV, Europe’s leading target discovery company, announced today that it has created a new business unit for…
Mechelen, Belgium, June 7th, 2004 — Galapagos Genomics NV, Europe’s leading target discovery company, announced today that it has identified, validated and filed patent applications…
Galapagos will build a number of Alzheimer’s Disease relevant assays using neuronal cells and will use these in combination with its adenoviral based target discovery…
Mechelen, Belgium, December 16, 2003 – Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the Companies will collaborate…
Mechelen, Belgium, November 13, 2003 –Galapagos Genomics today announced that it has entered into a discovery alliance in the field of osteoporosis with Wyeth Pharmaceuticals,…
Mechelen, Belgium, 11 November 2003 — Boehringer Ingelheim and Galapagos Genomics have entered into a collaboration in the field of antiviral discovery research. Under the…
Mechelen, Belgium, October 16, 2003 – Galapagos Genomics today announced that it has published its adenoviral siRNA based gene silencing technology in the scientific journal…
Mechelen, Belgium, June 11, 2003 — Galapagos Genomics, a privately held functional genomics company, today announced that it has entered into collaboration with Procter &…
Leiden, The Netherlands, May 13, 2003. Galapagos Genomics, the Netherlands/Belgian functional genomics company, today announced the launch of their human full-length gene adenoviral expression library…
London, UK, and Mechelen, Belgium, April 29, 2003 – Inpharmatica Ltd a leading informatics-driven drug discovery company, and Galapagos Genomics NV, the Belgian functional genomics…
Mechelen, Belgium and Freising, Germany, April 7, 2003. Galapagos Genomics NV, the Belgian functional genomics company, and Degussa BioActives announced today that they have entered…